Navigation Links
CBR Pharma Insights' Latest Report, The New Era of Healthcare Reform - Supporting Revenue Growth through Understanding & Adaptation
Date:7/1/2010

In the latest report from CBR Pharma Insights, the new healthcare reform legislation which was finally passed earlier this year is analyzed to provide pharmaceutical & biotech companies with a comprehensive set of tools to support their current and future business plans.

(PRWEB) July 1, 2010 -- After a hotly contested national debate, healthcare reform legislation was passed in the spring of 2010. The legislation contains many long-term benefits for the pharmaceutical industry, but the industry must continue to play an active role in legislation implementation to ensure those benefits are realized.

Through the new laws, there are both wins and losses for the pharmaceutical industry, such as changes effecting Medicare/Medicaid, health insurance coverage expansion & protection, taxation and patent protection. However, on balance most changes hold significant long-term potential for the industry.

While pharma played a very important role in promoting health reform during the debate over change, the work is not done. Many of the greatest potential benefits of the legislation – including extending healthcare coverage to 32 million more Americans – will come down the road. Thus, it is crucial for pharma to remain involved with the healthcare reform roll-out going forward.

Use CBR Pharma Insights' new report, "The New Era of Healthcare Reform - Supporting Revenue Growth through Understanding and Adaptation" to:

 
  • Analyze the possible impact that the new healthcare reform legislation could have on your company’s future growth potential
  • Assess the role pharmaceutical companies need to play to best ensure that all potential benefits are actually realized
  • Learn the pitfalls for the pharmaceutical industry to avoid as the new legislation is rolled-out
  • Identify the opportunities for growth in the new reform environment
  • Understand the ways the new healthcare reform bill can help change how healthcare is delivered in the United States

For more information about this report, please go to: http://www.cbrpharmainsights.com/inner/StrategicVisionProducts/CBRSV014pg.html

About CBR Pharma Insights - CBR Pharma Insights is a strategic market research firm whose mission is to empower companies to make the best business decisions possible through providing them with quality, innovative market research solutions. www.cbrpharmainsights.com

###

Read the full story at http://www.prweb.com/releases/2010/07HealthcareReform/prweb4211594.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
2. Therapure Biopharma Inc. Signs Biomanufacturing Contract with Diamedica Incorporated
3. Dragon Pharma announces date of special meeting
4. Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life
5. Progenika Biopharma Grants Grifols World-Wide Distribution Rights for the BLOODCHIP® Genotyping Test for Blood Donors
6. Angiotech Pharmaceuticals Announces Conference Call and Webcast
7. Three Top 20 Pharmaceutical Companies Select iCardiac as Preferred Vendor
8. Sosei to Acquire Activus Pharma
9. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
10. Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
11. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CBR Pharma Insights' Latest Report, The New Era of Healthcare Reform - Supporting Revenue Growth through Understanding & Adaptation 
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):